CRMD Q4 2024 Earnings — CorMedix Inc. Revenue & Financial Results | Market Cap Arena

CRMDCorMedix Inc.

$536M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$31M

Gross Profit

$30M96.2% margin

Operating Income

$13M41.4% margin

Net Income

$13M43.1% margin

EPS (Diluted)

$0.22

QoQ Revenue Growth

+172.4%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$119M

Total Liabilities

$34M

Stockholders' Equity

$85M

Cash & Equivalents

$41M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$31M	$0	—
Gross Profit	$30M	-$53,507	+56231.7%
Operating Income	$13M	-$16M	+182.6%
Net Income	$13M	-$15M	+191.3%